IP Library Granted Patent US 12,247,249
Granted Patent B2
US 12,247,249 · App. 17/311,972 · Granted Mar 11, 2025

Method for amplifying a genomic sample

Inventors: Samuel Woodhouse (Cambridge, GB); Giovanni Marsico (Cambridge, GB); Vincent Plagnol (Cambridge, GB); Stefanie Lensing (Cambridge, GB)
Assignee: INIVATA LTD.
C12Q1/6827C12Q1/6883C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,249
App. No.
17/311,972
Granted
Mar 11, 2025
Kind
B2
Abstract

Provided herein is method for, among other things, estimating the number of sequence variations in a sample of DNA. In some embodiments, the method can be used to estimate the mutational load of a sample. In some embodiments, the method makes use of a set of primers that have 3′ ends that specifically hybridizes to a sequence that is repeated multiple times in the genome. Thermocycling a reaction mix containing the primers may produce a reaction product comprising at least 50 amplicons having a total length of at least 100 kb. This product can be sequenced to provide an estimate of the number of sequence variations in the sample, and thus the mutational load of the sample.

Claims (30)

1. A method for amplifying a sample, comprising:

(a) combining a sample of cfDNA from the blood of a human with a thermostable polymerase, dNTPs and a set of at least 10 primers to produce a reaction mix, wherein:

(i) the 3′ end of each primer specifically hybridizes to a sequence that is repeated at least 20 times in the human genome,

(ii) the binding sites for the primers on opposite strands of the human genome have a median interval in the range of 50-114 nucleotides; and

(iii) collectively, the set of primers amplifies at least 50 regions having a total length of at least 100 kb, in a polymerase chain reaction using the human genome as a template; and

(b) subjecting the reaction mix to thermocycling to produce a reaction product comprising at least 50 amplicons having a total length of at least 100 kb.

2. The method of claim 1 , further comprising:

(c) sequencing the amplicons of step (b) or amplification products thereof to produce sequence reads; and

(d) analysing the sequence reads to identify sequence variations in the regions of the human genome amplified in step (b).

3. The method of claim 2 , further comprising (e) determining the number of sequence variations in the regions amplified in step (b).

4. The method of claim 2 , wherein the sequence variations are mutations.

5. The method of claim 2 , wherein the sequence variations are polymorphisms.

6. The method of claim 1 , further comprising:

(c) sequencing the amplicons of step (b) or amplification products thereof to produce sequence reads; and

(d) analysing the sequence reads to identify copy number variations in the regions of the human genome amplified in step (b).

7. The method of claim 1 , wherein the sample of DNA is a sample of cfDNA from maternal blood.

8. The method of claim 7 , wherein the method comprises:

(c) sequencing the amplicons of step (b) or amplification products thereof to produce sequence reads; and

(d) analysing the sequence reads to detect a foetal aneuploidy.

9. The method of claim 8 , wherein the method is done by detecting an increase in copy number of the amplicons amplified from chromosomes 21, 18 and/or 13, relative to a reference region.

10. The method of claim 1 , wherein the human is an organ transplant recipient.

11. The method of claim 10 , wherein the method comprises detecting a change in copy number of amplicons amplified from cfDNA from the transplanted organ.

12. The method of claim 1 , wherein the 3′ terminal 12 nucleotides of each primer are repeated at least 50 times in the human genome.

13. A set of at least 10 primers, wherein:

the 3′ end of each primer specifically hybridizes to a sequence that is repeated at least 20 times in the human genome,

the binding sites for the primers on opposite strands of the human genome have a median interval in the range of 50-114 nucleotides; and

collectively, the set of primers amplifies at least 50 regions having a total length of at least 100 kb, in a polymerase chain reaction using the human a genome as a template,

wherein some but not all of the primers comprise a first 5′ tail and the reminder of the primers comprise a second 5′ tail.

14. The set of primers of claim 13 , wherein the 3′ terminal 12 nucleotides of each primer are repeated at least 50 times in the human genome.

15. The set of primers of claim 13 , wherein the primers are in a mixture.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: WOODHOUSE, SAMUEL; MARSICO, GIOVANNI; PLAGNOL, VINCENT; LENSING, STEFANIE
To: INIVATA LTD.
Reel/Frame 056491/0540 →
Continuity (2)
Continuation In Part 16230609 · Dec 21, 2018
Related Publication 20220056508A1 · Feb 24, 2022
References Cited (23)
US 10053729B2 · Vogelstein et al. · 2018 [cited by applicant]
US 10533214B2 · Woodhouse · 2020 [cited by examiner]
US 20120070832A1 · Green et al. · 2012 [cited by applicant]
US 20120270739A1 · Rava · 2012 [cited by examiner]
US 20130060483A1 · Struble · 2013 [cited by examiner]
US 20170183731A1 · Mann · 2017 [cited by examiner]
Suyama et al., “MIG-seq: an effective PCRbased method for genome-wide single-nucleotide polymorphism genotyping using the next generation sequencing platform,” Scientific Reports, vol. 5, pp. 1-12. (Year: 2015). [cited by examiner]
Suyama Supplementary Information. (Year: 2015). [cited by examiner]
Takara Bio, “Multiplex PCR Assay Kit Ver.2,” pp. 1-9. (Year: 2015). [cited by examiner]
Allgäuer et al., “Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians”, Transl Lung Cancer Res, 2018, 7(6):703-715. [cited by applicant]
Campesato et al., “Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice”, Oncotarget, 2015, 6(33): 34221-34227. [cited by applicant]
Meléndez et al., “Methods of measurement for tumor mutational burden in tumor tissue”, Transl Lung Cancer Res, 2018, 7(6):661-667. [cited by applicant]
Rizvi et al, “Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer”, Science, 2015, 348(6230): 124-128. doi:10.1126/science.aaa1348. [cited by applicant]
Belic et al., “Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach”, Clinical Chemistry, 2015, 61:6, pp. 838-849. [cited by applicant]
Buttner et al., “Implementing TMB measurement in clinical practice: considerations on assay requirements”, ESMO Open, 2019, 4:e000442, pp. 1-12. [cited by applicant]
Elazezy et al., “Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management”, Computational and Structural Biotechnology Journal, 2018, 16: 370-378. [cited by applicant]
Kinde et al., “FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing”, PLoS ONE, 2012, 7(7): e41162, pp. 1-8. [cited by applicant]
Kinde et al., “FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing”, PLoS ONE, 2012, 7(7): e41162, suppl. Table S2. [cited by applicant]
Li et al., “Development of Three Multiplex PCR Primer Sets for Ark Shell ( [cited by applicant]
Palmirotta et al., “Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology”, Therapeutic Advances in Medical Oncology, 2018, 10: 1-24. [cited by applicant]
Wang et al., “Selection and development of representative simple sequence repeat primers and multiplex SSR sets for high throughput automated genotyping in maize”, Chinese Science Bulletin, 2007, 52(2): 215-223. [cited by applicant]
Weising et al., “A set of conserved PCR primers for the analysis of simple sequence repeat polymorphisms in chloroplast genomes of dicotyledonous angiosperms”, Genome, 1999, 42: 9-19. [cited by applicant]
American Cancer Society, “Immune checkpoint inhibitors to treat cancer”, downloaded from www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html, 2018, pp. 1-… [cited by applicant]